Sugi Predict

Sugi Predict / Compounds / SCHEMBL6318339

SCHEMBL6318339

SCHEMBL6318339

CCCC=CS(=O)(=O)NC(=O)c1ccc2[nH]c(C)c(Cc3ccc(C(F)(F)F)cc3Cl)c2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN5A Q14524 2/20 0.41
▸ SCN9A Q15858 2/20 0.41
▸ EPHX2 P34913 3/20 0.38
▸ NR1H4 Q96RI1 3/20 0.38
▸ MRGPRX4 Q96LA9 1/20 0.38
▸ MCL1 Q07820 2/20 0.36
▸ MAPT P10636 2/20 0.36
▸ PPARG P37231 4/20 0.35
▸ SNCA P37840 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ PTGS2 P35354 1/20 0.35
▸ TP53 P04637 1/20 0.34
▸ PTPN5 P54829 1/20 0.34
▸ SCN2B O60939 1/20 0.34
▸ SCN1A P35498 1/20 0.34
▸ SCN1B Q07699 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5882143 0.89 PPARG (0.40) MCL1MAPTPPARGSNCAPTGS2
SCHEMBL5882138 0.89 PPARG (0.40) MCL1MAPTPPARGSNCAPTGS2
SCHEMBL6318588 0.88 SCN5A (0.40) SCN5ASCN9AEPHX2NR1H4MRGPRX4
SCHEMBL6319284 0.88 SCN5A (0.40) SCN5ASCN9AEPHX2NR1H4MRGPRX4
SCHEMBL6322250 0.87 CXCR2 (0.38) MCL1MAPTPPARGSNCAMEN1
SCHEMBL6322000 0.87 PPARG (0.45) SCN5ASCN9AEPHX2NR1H4MRGPRX4
SCHEMBL6135287 0.83 SCN5A (0.42) SCN5ASCN9AEPHX2NR1H4MRGPRX4
SCHEMBL6320424 0.82 SCN5A (0.39) SCN5ASCN9AEPHX2NR1H4MRGPRX4
SCHEMBL6319329 0.81 PPARG (0.42) SCN5ASCN9AEPHX2NR1H4MRGPRX4
SCHEMBL6326861 0.80 PTPN5 (0.52) EPHX2NR1H4MRGPRX4MAPTPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050171185-A1 Indole derivatives FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION 2005-08-04 — — US claimed
EP-1070705-A1 INDOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-24 — — EP claimed
US-20050209278-A1 Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors PHARMACIA CORPORATION 2005-09-22 — — US disclosed
US-20050171185-A1 Indole derivatives FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION 2005-08-04 — — US disclosed
EP-1070705-A1 INDOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209278-A1 Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors MMP1, PREP, MMP3 SCN5A 3940/4885SCN9A 3002/4885EPHX2 431/4885
US-20050171185-A1 Indole derivatives PDE5A, IGFBP5, HTR5A SCN5A 59/4885SCN9A 1847/4885EPHX2 3905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.